viral and bacterial infections. The spokesperson of the cluster of excellence is Professor Dr. Thomas Schulz, head of the MHH Institute of Virology. More information is available here: www.RESIST-cluster

interaction with the immune system down to the smallest detail. RESIST spokesperson is Professor Dr. Thomas Schulz, head of the MHH Institute of Virology. RESIST is funded by the German Research Foundation (DFG)

smallest detail. RESIST consists of six partner institutions, the spokesperson is Professor Dr. Thomas Schulz, head of the MHH Institute of Virology. RESIST is funded by the German Research Foundation (DFG)

smallest detail. RESIST consists of six partner institutions. The spokesperson is Professor Dr Thomas Schulz, head of the MHH Institute of Virology. RESIST is funded by the German Research Foundation (DFG)

Understanding the Mode of Action of a novel broadly acting antiviral inhibitor Supervisor: Prof. Dr. Thomas Schulz, Institute of Virology, MHH Academic Background: Oncology, Sichuan University, China Lena Wolpert [...] the mode-of-action of the human RNase 7 against herpes simplex virus type 1 Supervisor : Prof. Dr. Thomas Werfel, Clinic for Dermatology, Allergology and Venerology, MHH Academic Background : Molecular Biology

smallest detail. RESIST consists of six partner institutions. The spokesperson is Professor Dr Thomas Schulz, head of the MHH Institute of Virology. RESIST is funded by the German Research Foundation (DFG)

are dedicated to COVID-19 / SARS-CoV-2. Projekt leaders are: Prof. Dr. Thomas F. Schulz, Prof. Dr. Gisa Gerold, Prof. Dr. Thomas Pietschmann, Prof. Dr. Gerard Krause, Prof. Dr. Jens Bosse, Prof. Dr. Abel

genetic and developmental aspects of congenital bone marrow failure syndromes Final exam November 2006 Thomas Gebhardt (Dr. med.) GERMANY supervisor: Prof. Dr. Bischoff, Gastroenterology and Hepatology OE 6810 [...] Protein profile of breast cancer Final exam November 2005 Linding Wang CHINA supervisor: Prof. Dr. Schulz, Virology, project: Transposon and targeted mutagenesis of a recombinant KSHV genome to identify

of human neutralizing monoclonal antibodies against SARS-CoV-2 Project leader: Prof. Dr. med. Thomas F. Schulz Department / Institute: Institute of Virology We want to generate broadly neutralizing, i.e [...] n of antiphage antibodies. Broad-spectrum compounds against SARS-CoV-2 Project leader: Prof. Dr. Thomas Pietschmann Department / Institute: Institute of Experimental Virology - TWINCORE In recent years [...] Förster's team aims to initiate a phase I clinical study. MWK COVID-19 cohort Project leader: Prof. Dr. Thomas Illig Department / Institute: Hannover Unified Biobank (HUB) A consortium of scientists and physician

S2352-3964(20)30260-7 Scholz KH, Lengenfelder B, Thilo C, Jeron A, Stefanow S, Janssens U, Bauersachs J, Schulze PC, Winter KD, Schroder J, Vom Dahl J, von Beckerath N, Seidl K, Friede T, Meyer T. Impact of COVID-19 [...] Re-purposing with a purpose. J Mol Cell Cardiol 2020;146:41-42 DOI: S0022-2828(20)30227-3 Jendrny P, Schulz C, Twele F, Meller S, von Kockritz-Blickwede M, Osterhaus ADME, Ebbers J, Pilchova V, Pink I, Welte [...] Domenico E, Wendisch D, Grasshoff M, Kapellos TS, Beckstette M, Pecht T, Saglam A, Dietrich O, Mei HE, Schulz AR, Conrad C, Kunkel D, Vafadarnejad E, Xu CJ, Horne A, Herbert M, Drews A, Thibeault C, Pfeiffer